atai Life Sciences announced the U.S. FDA cleared an Investigational New Drug (IND) to conduct a clinical drug-drug interaction (DDI) study of PCN-101 (R-ketamine). atai…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.